diversity (Crohn’s)

The DIVERSITY1 study is evaluating an oral investigational drug called filgotinib for people with moderate to severe Crohn’s disease. Filgotinib is an investigational drug called a "JAK1 inhibitor" that is taken as a pill once a day. JAK1 is a protein inside certain cells, including immune cells, which may stimulate their activity. When these immune cells are overactive, they can cause inflammation and trigger symptoms such as abdominal pain and diarrhea. This clinical research study will help determine if filgotinib improves the signs and symptoms of Crohn’s disease.

Participants who complete DIVERSITY1 may have the opportunity to enroll in a long-term extension study in which they will continue to receive the study drug they have been assigned. More information about DIVERSITY1 can also be found at clinicaltrials.gov

Could I qualify for DIVERSITY1?

Participants must:

● Be currently experiencing symptoms such as diarrhea or abdominal pain

● Be diagnosed with Crohn’s disease

● Be 18 to 75 years of age

● Meet eligibility criteria during screening at a participating doctor’s office